Jarno Drost Group

Jarno Drost

Oncode Investigator at Princess Máxima Center

My Research

Jarno Drost obtained his Master’s degree in Biomedical Sciences cum laude in 2005 from the Free University in Amsterdam. He received his PhD from the Erasmus University Rotterdam for his work on the identification of new tumor suppressor genes in the P53 pathway in the research group of Reuven Agami at the Netherlands Cancer Institute in Amsterdam.

Subsequently, Jarno joined the group of Hans Clevers at the Hubrecht Institute for his postdoctoral training where he exploited the organoid technology for cancer research. He developed colorectal cancer (CRC) progression models by introducing combinations of the most commonly mutated CRC genes in human small intestinal and colonic organoids using CRISPR/Cas9 genome editing. He used these models to study multistep tumorigenesis. For his work he received an NWO/Veni fellowship and the Dr. Patrick Hanlo Award for best postdoctoral researcher of the Hubrecht Institute.

In November 2016, he became a group leader at the Princess Máxima Center for pediatric oncology. His group studies the molecular alterations underlying pediatric solid tumors and uses novel pre-clinical model systems to identify therapeutic targets for the treatment of children with renal and rhabdoid tumors. He was granted a Bas Mulder young investigator award from the Dutch Cancer Society (KWF) and an ERC Starting grant.


  • 2019: European Research Council (ERC) Starting Grant
  • 2017: Dr. Patrick Hanlo Award for best postdoctoral researcher of the Hubrecht Institute
  • 2016: Bas Mulder young investigator award from the Dutch Cancer Society (KWF)
  • 2014: NWO (Netherlands organization for scientific research) VENI award

Key Publications

  1. Calandrini, C., Schutgens, F., Oka, R., Margaritis, T., Candelli, T., Mathijsen, L., Ammerlaan, C., van Ineveld, R.L., Derakhshan, S., de Haan, S., Dolman, E., Lijnzaad, P., Custers, L., Begthel, H., Kerstens, H.H.D., Visser, L.L., Rookmaker, M., Verhaar, M., Tytgat, G.A.M., Kemmeren, P., de Krijger, R.R., Al-Saadi, R., Pritchard-Jones, K., Kool, M., Rios, A.C., van den Heuvel-Eibrink, M.M., Molenaar, J.J., van Boxtel, R., Holstege, F.C.P., Clevers, H., Drost, J.#. An Organoid Biobank for Childhood Kidney Cancers that Captures Disease and Tissue Heterogeneity. Nature Communications 2020, in press.
  2. Drost, J.#, Clevers, H. Organoids in cancer research. Nature Reviews Cancer 2018 Jul, 18(7): 407-418.
  3. Fumagalli, A., Suijkerbuijk, S.J.E., Begthel, H., Beerling, E., Oost, K.C., Snippert, H.J., van Rheenen, J.#, Drost, J.#. A surgical orthotopic organoid transplantation approach in mice to visualize and study colorectal cancer progression. Nature Protocols 2018 Feb, 13(2): 235-247. PMID: 29300390
  4. Drost, J.*, van Boxtel, R.*, Blokzijl, F., Mizutani, T., Sasaki, N., Sasselli, V., de Ligt, J., Behjati, S., Grolleman, J.E., van Wezel, T., Nik-Zainal, S., Kuiper, R.P., Cuppen, E., Clevers, H. Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer. Science 2017 Oct 13, 358(6360): 234-238. PMID: 28912133
  5. Drost, J., van Jaarsveld, R.H., Ponsioen, B., Zimberlin, C., van Boxtel, R., Buijs, A., Sachs, N., Overmeer, R.M., Offerhaus, G.J., Begthel, H. Korving, J., van de Wetering, M., Schwank, G. Logtenberg, M., Cuppen, E., Snippert, H.J., Medema, J.P., Kops, G. J. P. L., Clevers, H. Sequential cancer mutations in cultured human intestinal stem cells. Nature 2015 May 7, 521(7550):43-47. PMID: 25924068
Contact Information
Jarno Drost Oncode Investigator

More Research

Research Strategy
Focus and Approach
Over 800 scientists working under a single strategy. Oncode is all about uniting efforts and bringing focus to research.
Support Programme
Our supporting programmes
New plans that help fulfil Oncode's objectives get our full support. Young talents are matched with mentors on the basis of their personal endeavours.
Research Groups
Our Groups
We firmly believe in sharing knowledge. From experienced veterans to talented young researchers, we work together in 61 groups.